| dc.contributor | 心理學系 | - |
| dc.creator (作者) | 林志陵 | zh_TW |
| dc.creator (作者) | Lin, Chih-Lin | en_US |
| dc.date (日期) | 2018-08 | - |
| dc.date.accessioned | 24-Jul-2018 16:46:02 (UTC+8) | - |
| dc.date.available | 24-Jul-2018 16:46:02 (UTC+8) | - |
| dc.date.issued (上傳時間) | 24-Jul-2018 16:46:02 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/118861 | - |
| dc.description.abstract (摘要) | To the Editor:We read with great interest the article entitled “Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.” by Hsu et al. in the December 2017 online edition.1 Over the past decades, antiviral therapies have dramatically improved long-term outcomes of chronic hepatitis B (CHB). For HBeAg-positive patients, early HBeAg seroconversion is an important treatment end point for a promising outcome. Through immune modulatory effect, pegylated interferon (PEG-IFN) achieved higher rates of HBeAg seroconversion than nucleos(t)ide analogues (NA). However, the response rate of PEG-IFN is unsatisfactory. Therefore, combination therapies may have potential benefits. | en_US |
| dc.format.extent | 155982 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 117(8), 745-746 | - |
| dc.title (題名) | Combination therapy for chronic hepatitis B: The future and beyond | en_US |
| dc.type (資料類型) | article | en |
| dc.identifier.doi (DOI) | 10.1016/j.jfma.2018.04.006 | - |
| dc.doi.uri (DOI) | https://doi.org/10.1016/j.jfma.2018.04.006 | - |
